Seeking Late Preclinical Oncology Assets: Small Molecules with IND-enabling Data and Patient Stratification Potential

Cumulus Oncology is seeking small molecule oncology assets that are at or near the IND-enabling stage and supported by GLP toxicology data, a defined biomarker strategy, and has potentially started GMP synthesis. In particular, their goal is to identify programs with strong translational relevance and a clear path to early clinical proof of concept.

Approaches of Interest:

• Ideal assets will have a well-characterized mechanism of action and potential for monotherapy or rational combinations
• Assets with defined biomarkers to support patient selection will be prioritized 
• Assets attracted to targets that have multi-indication potential are of interest – for example, inflammation-driven cancer pathways 
• Small molecule assets are of highest interest 

Out of Scope:

• Diagnostic‑only approaches

Developmental Stages of Interest:

• Opportunities from late preclinical research stage to Phase I stage are within scope. Opportunities that involve novel targets and demonstrate in vivo efficacy in solid tumor models.

Submission Information

Submission of one-page, 200–300-word briefs are encouraged, along with any optional supplementary information e.g., relevant publications. Submissions from academic institutes must be supported by GLP toxicology data. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, where any of: partnership (co-funding), licensing and asset purchase are options. Collaboration terms will be tailored on a case-by-case basis based on asset maturity, strategic alignment, and development potential.